Scientific Industries Inc
scientificindustries.comScientific Industries Inc (SCND) is a laboratory instruments and bioprocessing equipment company that designs, manufactures, and markets products across two operating segments: Benchtop Laboratory Equipment Operations and Bioprocessing Systems Operations. Revenue comes from transactional product sales in both segments, with the Benchtop Laboratory Equipment segment also generating earn-out income under a Manufacturing and Supply Agreement following the August 2025 sale of the Genie Division assets to Troemner, LLC for $9.6 million plus up to $1.5 million in earn-out consideration. The Bioprocessing Systems Operations, conducted through subsidiary SBHI and its wholly-owned subsidiaries SBI and Aquila, focuses on bioprocessing product design, development, and manufacture. Customer concentration is material: the top Benchtop Laboratory Equipment customer accounted for approximately 42% of that segment's total sales and 31% of consolidated net revenues for the year ended December 31, 2025. The company holds IP developed partly under a license agreement with the University of Maryland, Baltimore County. Helena Santos serves as President and Chief Executive Officer.
Products & Services
Benchtop laboratory equipment (formerly including the Genie Division, sold to Troemner, LLC in August 2025); Torbal-branded products through the Torbal Products Division; bioprocessing products designed, developed, and manufactured through SBI and Aquila subsidiaries under the Bioprocessing Systems Operations.
Revenue Model
Transactional product sales across Benchtop Laboratory Equipment and Bioprocessing Systems segments. Additional earn-out income recorded under a Manufacturing and Supply Agreement with Troemner, LLC following the Genie Division asset sale; $300,000 earned under that agreement as of December 31, 2025.
Customers & Markets
Laboratory and life sciences end markets. Top Benchtop Laboratory Equipment customer represented approximately 42% of segment sales and 31% of consolidated net revenues for the year ended December 31, 2025. Bioprocessing customers in the biopharmaceutical and bioprocessing market.
Geographic Exposure
Primary operations in the United States, with foreign currency translation adjustments indicating some international exposure. Specific geographic revenue split not disclosed in the filing excerpts.
Financial Snapshot
Loading...
